In breast and ovarian cancers, for which methylation analysis is most often conducted, promoter methylation of BRCA1 accounts for at least 20% of explained biallelic inactivation cases of HRD, labeled by either of the classifiers, and lack of methylation data significantly affects the performance of classifiers. The gene discussed is BRCA1; the disease is ovarian carcinoma.